Evelyn Ullrich
Overview
Explore the profile of Evelyn Ullrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5918
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klett A, Raith D, Silvestrini P, Stingl M, Bermeitinger J, Sapre A, et al.
Front Oncol
. 2025 Mar;
15:1520972.
PMID: 40046624
Introduction: The colony forming assay (CFA) stands as a cornerstone technique for evaluating the clonal expansion ability of single cancer cells and is crucial for assessing drug efficacy. However, traditional...
2.
Moser L, Heim C, Koschade S, Wendel P, Bozkurt S, Harenkamp S, et al.
Front Immunol
. 2025 Feb;
16:1485817.
PMID: 39963129
Introduction: CAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells. Cytokine-induced killer (CIK) cells can be given safely across...
3.
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M, et al.
Transfus Med Hemother
. 2025 Feb;
52(1):42-60.
PMID: 39944413
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve...
4.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann J, Seidl C, et al.
Front Immunol
. 2024 Dec;
15:1413927.
PMID: 39737173
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an...
5.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, et al.
Transplant Cell Ther
. 2024 Dec;
31(1):10.e1-10.e9.
PMID: 39667999
Background: The standard treatment for acute graft-vs-host disease (GVHD), a common complication following allogeneic hematopoietic cell transplant, remains prolonged courses of high dose corticosteroids. Previous attempts to decrease corticosteroid exposure...
6.
Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al.
Nat Commun
. 2024 Sep;
15(1):8439.
PMID: 39349459
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between...
7.
Zophel S, Kuchler N, Jansky J, Hoxha C, Schafer G, Weise J, et al.
Mol Cancer
. 2024 Sep;
23(1):210.
PMID: 39342291
Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which...
8.
Yao M, Ullrich E, Albini A
Front Immunol
. 2024 Sep;
15:1466010.
PMID: 39234252
No abstract available.
9.
Rios C, Qayed M, Etra A, Reshef R, Newcomb R, Yuhasz N, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1061.e1-1061.e10.
PMID: 39222793
Acute graft-versus-host disease (GVHD) is a significant complication following hematopoietic stem cell transplantation (HCT). Although recent advancements in GVHD prophylaxis have resulted in successful HCT across HLA barriers and expanded...
10.
Schoenfeld K, Habermann J, Wendel P, Harwardt J, Ullrich E, Kolmar H
Mol Ther Oncol
. 2024 Aug;
32(3):200850.
PMID: 39176070
T cell-derived cancers are hallmarked by heterogeneity, aggressiveness, and poor clinical outcomes. Available targeted therapies are severely limited due to a lack of target antigens that allow discrimination of malignant...